Pharmacogenomic considerations for repurposing of dexamethasone as a potential drug against SARS-CoV-2 infection

Manik Vohra, Anu Radha Sharma, Kapaettu Satyamoorthy, Padmalatha S. Rai

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Immunomodulatory and analgesic effects of dexamethasone are clinically well established, and this synthetic corticosteroid acts as an agonist of glucocorticoid receptors. Early results of the RECOVERY Trial from the United Kingdom and others suggest certain benefits of dexamethasone against COVID-19 chronic patients. The efforts have been acknowledged by World Health Organization with an interim guideline to use in patients with a severe and critical illness. The inherent genetic variations in genes such as CYP3A5, NR3C1, NR3C2, etc., involved in the pharmacokinetic and pharmacodynamic processes may influence dexamethasone's effects as an anti-inflammatory drug. Besides, the drug may influence transcriptome or metabolic changes in the individuals. In the present review, we summarize the reported genetic variations that impact dexamethasone response and discuss dexamethasone-induced changes in transcriptome and metabolome that may influence potential treatment outcome against COVID-19.

Original languageEnglish
Pages (from-to)389-398
Number of pages10
JournalPersonalized Medicine
Volume18
Issue number4
DOIs
Publication statusPublished - 07-2021

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology

Fingerprint

Dive into the research topics of 'Pharmacogenomic considerations for repurposing of dexamethasone as a potential drug against SARS-CoV-2 infection'. Together they form a unique fingerprint.

Cite this